Muscle Cells-based In Vitro Screening Service

Muscle Cells-based In Vitro Screening Service

Professional Muscle Cells-based In Vitro Screening That Exceeding Your Expectations

Whether our clients need In Vivo or In Vitro Glycobiology Disease Model Screening services, our Glycobiology Disease Model Development team provides you with the most satisfactory screening solutions. With advanced analytical systems and skillful in vitro cell-based modeling experience, CD BioGlyco provides muscle cell-based in vitro high-throughput screening services. Moreover, we provide myogenic cell models such as C2C12-cell models and L6-cell models. They are mature and stable cell culture models for in vitro screening. Meanwhile, C2C12 is also an insulin target cell.

  • Muscle cell culture and optimization
    • CD BioGlyco provides reliable muscle cell culture and condition optimization services. When the cells are cultured to 80-90% fusion, our staff ensures the induction of differentiation through professional operation.
    • For differentiated cells, CD BioGlyco provides cytokine gene expression in total RNA and cell viability assays.
  • Total protein estimation
    • Our lab uses the chloroacetic acid precipitation method to determine the total protein concentration in muscle cells. The samples to be tested and a standard solution of bovine serum albumin (BSA) are assayed three times using an ultraviolet-visible (UV/Vis) spectrophotometer measuring absorbance at 750 nm.
    • Our lab provides precise sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, colorimetric immunoblotting, and chemiluminescent immunoblotting analysis services.
  • Special analysis
    • Combining tandem mass-tag (TMT) and liquid chromatography-tandem mass spectrometry analysis, we offer high-throughput screening and quantification of individual or multiple samples. We evaluate genes, biomarkers, and glycosyltransferases by longitudinal analysis and differential expression analysis.
    • Our lab provides high-quality analysis including fluorometric quantification assay, enzyme-linked immunosorbent assay (ELISA), and electrophoretic mobility shift assay.

The workflow for proteome-wide analysis of C2C12 myoblast differentiation. (CD BioGlyco)

Publication

Technology: Western blot, Reversed-phase high-performance liquid chromatography (RP-HPLC), Liquid chromatography-mass spectrometry (LC-MS)

Journal: Journal of Proteome Research

Published: 2023

IF: 4.4

Results: In this study, researchers elaborated an in vitro mouse model of skeletal muscle differentiation by tandem mass labeling method to deal with myogenesis in C2C12 cells. By longitudinal analysis of tens of thousands of proteins found in C2C12 myogenesis, screening yielded a new subpopulation of 1062 myogenesis regulatory proteins. The results indicated a significant (homology) overlap of these regulatory proteins with similar analyses performed in human myoblasts. Further differential analysis of protein expression at each stage revealed a set of 198 proteins that were significantly differentially expressed in TMX-treated cells compared to controls.

Fig.1 Temporal proteome analysis and functional characterization of normal C2C12 myogenesis.Fig.1 Temporal proteome profiling of normal C2C12 differentiation. (Morris, et al., 2023)

Applications

  • Muscle cells-based in vitro screening can be used to develop important drug compounds and analyze drug delivery systems.
  • Muscle cells-based in vitro screening can be used for drug screening and target analysis.
  • Muscle cells-based in vitro screening can be used to elucidate target molecules associated with insulin resistance and regulation of motor mechanisms associated with glucose utilization in skeletal muscle.
  • Muscle cells-based in vitro screening plays a key role in the study of interactions in early skeletal muscle development.

Advantages of Us

  • Our state-of-the-art screening system provides our clients with a comprehensive assessment and analysis.
  • Our lab provides customized model development, and factor-specific screening services based on our clients' targeting screening and cell model development needs.
  • Our high-quality data analytics team guards every piece of data to ensure efficient and accomplished delivery.

CD BioGlyco provides a one-stop service for the development, construction, and screening of in vitro glycobiological disease models under the supervision of specialized personnel. We are committed to providing our clients with the most time-saving and efficient service possible. Please feel free to contact us.

Reference

  1. Morris, E.A.; et al. Effect of tamoxifen on proteome expression during in vitro myogenesis in murine skeletal muscle C2C12 cells. Journal of Proteome Research. 2023, 22(9): 3040-3053.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0